{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T23:54:58Z","timestamp":1785887698750,"version":"3.56.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministry of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.cgh.2026.04.033","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T07:37:03Z","timestamp":1779781023000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Predicting Decompensation in Unresectable Hepatocellular Carcinoma on Atezolizumab Plus Bevacizumab: The ARTE Score"],"prefix":"10.1016","author":[{"given":"Lorenzo","family":"Canova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Alimenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Argiento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Cabibbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Tovoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Di Giacomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter R.","family":"Galle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciro","family":"Celsa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Pinter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas U.","family":"Marron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Vivaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Dalbeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Marra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Palloni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Lonardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca Romana","family":"Ponziani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piera","family":"Federico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anwaar","family":"Saeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjana","family":"Pillai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziana","family":"Pressiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Camera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Svegliati-Baroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia Francesca","family":"Manfredi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Lani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann","family":"von Felden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Ulahannan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Ielasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"De Lorenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Mazzarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodolfo","family":"Sacco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natascha","family":"Rohlen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Silletta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierluigi","family":"Toniutto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Ascari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Fulgenzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Scheiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fionnuala","family":"Crowley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Cerini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Lampertico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David James","family":"Pinato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3493-6504","authenticated-orcid":false,"given":"Massimo","family":"Iavarone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2026.04.033_bib1","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jhep.2024.08.028","article-title":"EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma","volume":"82","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.cgh.2026.04.033_bib2","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","article-title":"AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma","volume":"78","author":"Singal","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2026.04.033_bib3","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.annonc.2025.02.006","article-title":"Hepatocellular carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"36","author":"Vogel","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cgh.2026.04.033_bib4","doi-asserted-by":"crossref","first-page":"e312","DOI":"10.1016\/S1470-2045(23)00186-9","article-title":"Personalised management of patients with hepatocellular carcinoma: a multiparametric therapeutic hierarchy concept","volume":"24","author":"Vitale","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cgh.2026.04.033_bib5","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.jhep.2025.10.020","article-title":"BCLC strategy for prognosis prediction and treatment recommendations: the 2025 update","volume":"84","author":"Reig","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.cgh.2026.04.033_bib6","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2026.04.033_bib7","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2026.04.033_bib8","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2026.04.033_bib9","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.cgh.2026.04.033_bib10","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100070","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"1","author":"Abou-Alfa","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.cgh.2026.04.033_bib11","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.annonc.2024.02.005","article-title":"Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"35","author":"Sangro","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cgh.2026.04.033_bib12","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.jhep.2025.03.033","article-title":"Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC","volume":"83","author":"Rimassa","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.cgh.2026.04.033_bib13","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/S0140-6736(25)00403-9","article-title":"Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial","volume":"405","author":"Yau","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2026.04.033_bib14","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1097\/HEP.0000000000001026","article-title":"Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: the impact of successful antiviral treatment","volume":"81","author":"Celsa","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2026.04.033_bib15","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","article-title":"Baveno VII - renewing consensus in portal hypertension","volume":"76","author":"de Franchis","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.cgh.2026.04.033_bib16","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1016\/j.cgh.2024.12.028","article-title":"Liver decompensation in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab: a real-life study","volume":"23","author":"Stella","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2026.04.033_bib17","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1097\/HEP.0000000000000205","article-title":"Evaluating the risk-benefit ratio of immunotherapy according to liver-functional reserve in advanced HCC: the dark side of the moon","volume":"77","author":"Cabibbo","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2026.04.033_bib18","first-page":"1","article-title":"Surgery and portal hypertension","volume":"1","author":"Child","year":"1964","journal-title":"Major Probl Clin Surg"},{"key":"10.1016\/j.cgh.2026.04.033_bib19","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1053\/jhep.2001.22172","article-title":"A model to predict survival in patients with end-stage liver disease","volume":"33","author":"Kamath","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2026.04.033_bib20","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1200\/JCO.2014.57.9151","article-title":"Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade","volume":"33","author":"Johnson","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cgh.2026.04.033_bib21","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1016\/j.dld.2024.07.035","article-title":"Suboptimal outcomes of sorafenib as a second-line treatment after atezolizumab-bevacizumab for unresectable hepatocellular carcinoma","volume":"56","author":"Tovoli","year":"2024","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.cgh.2026.04.033_bib22","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/j.jhep.2025.07.020","article-title":"Establishing hepatic decompensation as a meaningful clinical outcome during systemic therapy for hepatocellular carcinoma","volume":"83","author":"Cabibbo","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.cgh.2026.04.033_bib23","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1002\/hep.32468","article-title":"Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: a real-world study","volume":"76","author":"D\u2019Alessio","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2026.04.033_bib24","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.ejca.2022.08.024","article-title":"Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: results of the AB-real study","volume":"175","author":"Fulgenzi","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.cgh.2026.04.033_bib25","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1097\/HEP.0000000000000844","article-title":"AASLD Practice Guideline on noninvasive liver disease assessment of portal hypertension","volume":"81","author":"Sterling","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2026.04.033_bib26","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000534127","article-title":"Incidence and predictors of esophagogastric varices bleeding in patients with hepatocellular carcinoma in lenvatinib","volume":"13","author":"Iavarone","year":"2024","journal-title":"Liver Cancer"},{"key":"10.1016\/j.cgh.2026.04.033_bib27","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jhep.2005.10.013","article-title":"Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies","volume":"44","author":"D\u2019Amico","year":"2006","journal-title":"J Hepatol"},{"key":"10.1016\/j.cgh.2026.04.033_bib28","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.3390\/cancers11101568","article-title":"Platelets and hepatocellular cancer: bridging the bench to the clinics","volume":"11","author":"Lai","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.cgh.2026.04.033_bib29","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1158\/1078-0432.CCR-24-2582","article-title":"Early hepatic decompensation identifies patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab or sorafenib at highest risk of death","volume":"31","author":"Cabibbo","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cgh.2026.04.033_bib30","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.dld.2022.01.122","article-title":"Optimizing systemic therapy for advanced hepatocellular carcinoma: the key role of liver function","volume":"54","author":"Cabibbo","year":"2022","journal-title":"Dig Liver Dis"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356526003897?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356526003897?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T23:41:28Z","timestamp":1785886888000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356526003897"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":30,"alternative-id":["S1542356526003897"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2026.04.033","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predicting Decompensation in Unresectable Hepatocellular Carcinoma on Atezolizumab Plus Bevacizumab: The ARTE Score","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2026.04.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Gastroenterological Association Institute. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}